Categories: News

Extendicare Announces March 2022 Dividend of C$0.04 per Share

MARKHAM, Ontario, March 15, 2022 (GLOBE NEWSWIRE) — Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common Share”) for the month of March 2022, which is payable on April 15, 2022 to shareholders of record at the close of business on March 31, 2022. This dividend is designated as an “eligible dividend” within the meaning of the Income Tax Act (Canada).

About Extendicare

Extendicare is a leading provider of care and services for seniors across Canada, operating under the Extendicare, Esprit Lifestyle, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network brands. We are committed to delivering quality care throughout the health continuum to meet the needs of a growing seniors population. We operate or provide contract services to a network of 119 long-term care homes and retirement communities (69 owned/50 contract services), provide approximately 9.2 million hours of home health care services annually, and provide group purchasing services to third parties representing approximately 93,200 senior residents across Canada. Extendicare proudly employs more than 20,000 qualified, highly trained and dedicated individuals who are passionate about providing high-quality care and services to help people live better.

Forward-looking Statements
Information provided by Extendicare from time to time, including this release, contains or may contain forward-looking statements concerning anticipated future events, results, circumstances, economic performance or expectations with respect to Extendicare and its subsidiaries, including, without limitation, statements regarding its business operations, business strategy, growth strategy, results of operations and financial condition. Forward-looking statements can often be identified by the expressions “anticipate”, “believe”, “estimate”, “expect”, “intend”, “objective”, “plan”, “project”, “will” or other similar expressions or the negative thereof. These forward-looking statements the Company’s current expectations regarding future results, performance or achievements and are based upon information currently available to the Company and on assumptions that the Company believes are reasonable. The Company assumes no obligation to update or revise any forward-looking statement, except as required by applicable securities laws. These statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to differ materially from those expressed or implied in the statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on Extendicare’s forward-looking statements. Further information can be found in the disclosure documents filed by Extendicare with the securities regulatory authorities, available at www.sedar.com and on Extendicare’s website at www.extendicare.com.

Extendicare contact:
Jillian E. Fountain
Vice President, Investor Relations
Phone: (905) 470-5534
Email: jfountain@extendicare.com
www.extendicare.com

Staff

Recent Posts

ModMed Once Again Ranks #1 in All of its Specialty-Specific EHRs in the 2025 Black Book Survey

BOCA RATON, Fla.--(BUSINESS WIRE)--For the second year, practice technology leader ModMed® sweeps the Black Book™…

3 hours ago

LiveData PeriOp Manager Launched in 88 Veterans Affairs Hospitals

DSS Advances OR Efficiency and Patient Access to Surgery Across 85% of VA Medical Centers…

3 hours ago

Rapid Dose Completes Issuance of Shares as Payment of Directors’ Fees

Burlington, Ontario--(Newsfile Corp. - January 16, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or…

3 hours ago

ModMed Named Leader in Physician Practice EHR Software for 11 Specialties in 2025 Black Book Awards

TAMPA, FLORIDA / ACCESS Newswire / January 16, 2025 / ModMed continues to dominate the…

3 hours ago

Veos Pharmaceuticals Launches ThymoTropin™ to Support Muscle Health and Preservation on Weight Loss and Aging Journeys

Clinically Proven Myostatin-Targeting Formula to Enhance Muscle Growth, Repair, and Endurance MADRID, SPAIN / ACCESS…

3 hours ago

Progyny Appoints Healthcare Veteran Debra Morris to Board of Directors

NEW YORK, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility,…

3 hours ago